EDITOR,-The recent collaborative publication on the epidemiology of cerebral palsy, incorporating data from three cerebral palsy registers, categorises levels of functional disability to reflect diYculties with ambulation, manual dexterity, and learning.
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We agree that "...severity of disability needs to be recorded..." to facilitate comprehensive monitoring and rational planning, but a measure of how such disability aVects the life of a child would further improve our understanding.
The North of England Cerebral Palsy Register contains data on children born between 1960 and 1990 to mothers resident in Newcastle, Northumberland, and North Tyneside. This Register includes a unitary measure of impact of disability, comprising six contributing dimensions.
2 The functional disabilities described by Pharaoh and colleagues would be captured within the dimensions of mobility, physical independence, and schooling. We reviewed data on children born 1984-9, and identified interesting similarities and diVerences to the findings of Pharaoh et al.
During 1984-9, there were 57 605 live births in Newcastle, Northumberland, and North Tyneside. Among these live borns were 316 neonatal deaths and 125 cases of cerebral palsy, giving a neonatal mortality rate of 5.5 per 1000 live births and a cerebral palsy rate of 2.2 per 1000 neonatal survivors. Birthweight and clinical type of cerebral palsy were known for all children. Data on the impact of disability are available for 100/125.
Neonatal mortality and cerebral palsy prevalences are almost identical with those found by Pharaoh et al, as is the observation that the type of cerebral palsy diVers among diVerent birthweight groups, with the lightest and heaviest groups showing fewer cases of diplegia and more cases of hemiplegia (table 1) . Table 2 shows the severity of impact of disability for mobility, physical independence, and schooling. After excluding those of unknown severity, like Pharaoh et al we found that over 40% of children, irrespective of birthweight, have severe mobility problems. Unlike Pharaoh and his colleagues, however, we found no diVerences in physical independence among birthweight groups (14/51 children born > 2500 g vs 15/49 of those born < 2500 g had severe problems), and in our cohort, the proportion of children with severe educational problems increased with decreasing birthweight, corresponding to some of the findings of follow up studies of children with low birthweight. 3 4 We conclude that a measure of the impact of disability on the lives of children permits greater precision in describing the epidemiology of cerebral palsy.
Maternal hypertension and its association with cerebral palsy in very preterm infants

EDITOR,-Gray et al
1 recently reported an apparently new observation that "maternal hypertension has a protective eVect against cerebral palsy in very preterm infants." Do their data support this conclusion, which is diVerent from the conclusion reached by two other case control studies 2 3 on this topic? In the same issue, Tin et al 4 remind us that those infants who are diYcult to follow up have diVerent (worse) outcomes than those infants who could be followed up without great diYculty. They provide a key message that "studies where it is not possible to see some children for assessment might usefully include a calculation of what the total prevalence would be if there was a fivefold difference in the proportion with the condition in question among the children who were not seen."
Gray et al's study comprised 107 in the study group, of whom there were 101 survivors. At 2 years of age, four in the study group were lost to follow up as were two in the control group. Using the recalculation suggested by Tin et al, there is no longer a significant diVerence between the estimated incidence of cerebral palsy in the two groups. Spinillo 2 et al reported cerebral palsy in 2/92 (2.1%) cases and 4/184 (2.1%) controls. However, their two year follow up was 92 of 97 cases. Ascertainment of the outcomes of the remainder of the group, and applying Tin et al's "correction" would not have changed their conclusion of no diVerence in the incidence of cerebral palsy between infants born to hypertensive mothers and controls.
The case control study by Szymonowicz and Yu 3 reported 27 cases and 26 controls and came to exactly the same conclusion as Gray et al. All had a two year follow up, but it is not stated in their paper whether complete follow up was achieved or whether the sample was selected retrospectively on the basis of the availability of two year follow up data.
A prospective study designed to have 80% power to show a protective eVect of preeclampsia of 25% against cerebral palsy, assuming a 5% cerebral palsy rate in the control group, would require more that 4000 babies in each study arm. Even to detect a 50% reduction from a 10% rate of cerebral palsy in the controls would require about 500 babies in each arm. The combined number of babies of hypertensive mothers in the three case control studies is 216.
In view of Tin et al's timely demonstration of the importance of the eVects of incomplete follow up and the above considerations, it is prudent to await further prospective studies before accepting Gray et al's conclusion that "maternal hypertension has a protective effect against cerebral palsy in very preterm infants." 
Dr Gray responds:
Professor Colditz cited the report of Tin et al 4 and concluded that a recalculation of our data (on the basis of those infants lost follow up) would reveal that there would no longer be a statistical diVerence in the estimated incidence of cerebral palsy between study and control groups. While we reported neurodevelopmental outcome of the infants at 2 years, in general, cerebral palsy of functional significance can be reliably diagnosed by the age of 12 months, One of our four study infants not seen at 2 years was assessed at 1 year, while both control infants not seen at 2 years had follow up data at 1 year of age. None of these three infants had cerebral palsy. Thus cerebral palsy occurred in 0/98 (0%) study infants compared with 5/104 (4.8%) controls.
Tin et al suggested that one might include in results "a calculation of what the total prevalence would be it there was a fivefold difference in the proportion with the condition in question among children who are not seen." As the incidence of cerebral palsy in the study children was 0%, a fivefold increase would remain 0%. If, however, one calculated the incidence of cerebral palsy in the total population (5/202, 2.5%) and made a fivefold increase, the incidence of cerebral palsy would be 12.5% in those infants lost to follow up. Thus in both scenarios, of our three infants, less than one would be expected to have cerebral palsy and the significance between the groups would remain.
We acknowledge that our results are at variance with two previous cohort studies, 5 6 but they agree with the recent case control study of cerebral palsy in preterm infants. Murphy et al 7 found a decreased risk (relative risk 0.4; 95% confidence intervals 0.2-0.9) of cerebral palsy when maternal hypertension/preeclampsia was present. Accordingly, while a large multicentred cohort study would be useful, we believe that the current evidence does suggest that maternal hypertension protects against cerebral palsy in preterm infants. We therefore agree with Collins and Paneth, 8 who concluded in their annotation that preterm infants born to mothers with pre-eclampsia have a lower risk of cerebral palsy than other preterm infants. 3 recently failed to show a reduction in its incidence. None of these studies has considered the impact of the treatment on the rate of periventricular leucomalacia (PVL).
We used a protocol similar to Saunder's study design (0.25 mg/kg intravenously twice before 24 hours of life) in neonates born before 29 completed weeks of gestation with respiratory distress syndrome. This open study conducted over 20 months was interrupted after an important increase in cystic PVL rate had been observed. Indeed, the incidence of PVL during this period (15%) was significantly higher than that observed during both the preceeding 20 months (7%) and the following 20 months (7%) (p < 0.02). Moreover, during the same period (73 treated and 99 untreated infants), PVL rate was higher in group treated with dexamethasone (23% vs 9%; p < 0.05, 2 test after controlling for gestational age). Perinatal morbidity in the treated group was greater, but did not account for the higher PVL rate observed during the treatment period. Indeed, early neonatal mortality (< 7 days), the rates of respiratory distress syndrome, haemodynamic failure and congenital sepsis, as well as the circumstances of delivery known to be associated with high rate of PVL (premature rupture of the membranes, intrauterine infection, vaginal bleeding) were not statistically diVerent before, during, and after the treatment period.
Adverse eVects on neuromotor functions have already been reported by Yeh et al in an early prolonged trial of dexamethasone. 4 As far as the conflicting data of controlled trials on its benefits are concerned, early postnatal administration of dexamethasone should be considered with caution, as long as follow up results of other randomised studies are not yet available. OLIVIER 
Is caVeine treatment given to preterm babies a risk factor for SIDS?
EDITOR,-Ford et al 1 examined the association between maternal caVeine intake during pregnancy and the risk of sudden infant death and found a higher risk for babies whose mothers consumed more than 400 mg/day of caVeine during the first and/or the third trimester of pregnancy (with increased risk especially for the third trimester group).
We are concerned because preterm babies, especially those of low and very low birthweight, are routinely treated with caVeine or theophylline to prevent apnoea and brachycardia at a gestational time which is equivalent to the "third trimester of pregnancy." The question as to whether we can compare the dose given to the neonates with the 400 mg/day taken by pregnant women, the amount found to increase the risk of SIDS.
When we look at the common dose of caVeine citrate (between 3 mg/kg/day and 5 mg/kg/day, after a rather high loading dose) it seems to be somewhat lower than the amounts postulated in Ford's study (assuming that the pregnant woman weighs about 75 kg on average, 400 mg/day would be equivalent to 5.33 mg/kg/day in preterm infants, for example). However, even considering the higher distribution volumes, the pharmacokinetic studies with premature neonates 2 3 show a markedly lower clearance than the values reported for adults.
We have not been able to find any data for fetal serum concentrations of caVeine, but fetal values would be expected to decrease faster in utero than after delivery, owing to maternal excretion.
The possible explanation suggested for an increased risk of SIDS is the eVect of caVeine on the brainstem, which may cause increased vulnerability of the respiratory centre.
3 If this theory is right, we cannot find any basic diVerence in the situation of fetal and neonatal "treatment."
So, the question remains: is the higher incidence of SIDS in premature babies the result of neonatal caVeine treatment? 
Dr Ford et al respond:
CaVeine treatment for apnoea in prematurity is current standard neonatal practice. 4 Very premature infants have about a fivefold increased risk of SIDS compared with their full term counterparts. 5 6 Bock et al therefore speculate whether this higher incidence of SIDS in premature infants might be related to caVeine treatment. To our knowledge, there is no satisfactory answer to this question. However, as in all treatments, a balance needs
Impaired phagocytosis and opsonisation towards group B streptococci in preterm infants
EDITOR,-We were interested to see the article by Kallman et al, 1 who have elegantly demonstrated the role that defective polymorphonuclear leucocyte (PMNL) function and reduced opsonic capacity have, in sepsis caused by group B streptococcus in preterm infants. They advocate the need for a vaccine or passive transfer of opsonic antibody. One vaccination strategy has recently been tried in an animal model.
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There are, however, other potential therapeutic strategies. One of us has previously shown that PMNL respiratory burst activity is reduced in preterm infants 3 compared with term infants and adults, but can be increased ("primed") by prior exposure to cytokines (rhGM-CSF). Therefore, an alternative approach in treatment is to enhance defective PMNL function with the administration of growth factors or cytokines, and we understand trials of this nature are currently in progress.
These observations highlight the need for further investigation of the mechanisms underlying the relative immunodeficiency of preterm infants as a basis for rational treatment. Even if a vaccine proves to be the most eYcient treatment it can only work against the background of the child's own immunological responsiveness.
MERVYN S JASWON DAVID R KATZ Departments of Paediatrics and Immunology
University College London Medical School This is the third edition of a well recognised neonatal handbook. The authors declare their intention to provide a book of a practical nature as a ward guide for medical and nursing staV caring for newborn infants. Much revision has occurred since the previous edition and the depth and breadth of contributions is reflected in the lengthy list of editors and contributors, all of whom are recognised as experienced practitioners.
Have the editors succeeded in their aim? Essentially, yes. The book is of a size and price to be readily accessible. It is very clear in its layout and provides essential neonatal information a shopfloor neonatologist needs. Each section has a useful bibliography as a source for more extensive information.
My main criticism is questionable information. A brief introductory sentence pointing out that local practices may be at variance with those detailed, and should be respected, would be helpful to junior and nursing staV. Some of the information is set out didactically with no hint that there is a wide body of practice. Instances would be the roles of ultrasound and serum screening in antenatal practice, the use of Ribavarin for RSV bronchiolitis, and the choice of anticonvulsants for seizures. There is little evidence that outcome in perinatal asphyxia is helped by the use of therapies to reduce raised intracranial pressure, so mannitol is not used in many centres. The value of cerebral ultrasound in determining cerebral oedema is very questionable and it is now recognised that antenatally diagnosed cystic adenomatous malformations of the lung can regress, obviating the need for lobectomy. The infusion dose of tolazoline is given as 0.1 mg/kg/hour; do they mean this or is this a printing error? These are minor quibbles as most of the management decisions relating to these points will be conducted at a senior level, but for juniors who use this book it would be helpful to know that not all questions have only one answer.
The one area in which it is important to state the opinion given is contentious, is the use of 40%, rather than 100% oxygen for resuscitation. It is important that all personnel called on to resuscitate newborns are aware of the local policy.
The sections on caring for the family and the dying baby are extremely well written, particularly when considering the size and scope of the book. I recommend anyone working in this area to read them. The ethical and personal issues which have to be faced are clearly, succinctly and compassionately addressed.
The editorial team should be congratulated on producing such a compact yet useful book which, I am sure, will find its way onto many neonatal units. "Much study is a weariness of the flesh" stated the writer from Ecclesiastes. The acquisition of medical knowledge requires the consumption of many large, indigestible tomes. This compact textbook on critical care of the surgical newborn provides a suitable antidote. It is small, concise, light in weight, but packs a quality punch. It is a good balance of relevant embryology, antenatal diagnosis, appropriate investigations, and operative management. From a surgical perspective I found the chapters on prenatal diagnosis and ultrasound particularly useful, teaching me many things I probably ought to have known already.
It covers the usual range of child topics on neonatal care well and succinctly and in a sufficiently diVerent way to be interesting. It also discusses ethics and anaesthetics and analgesia. The chapter on anaesthetics finally answered a question I have asked every anaesthetist but to which I have never received a satisfactory reply-namely, what is the intraoperative/anaesthetic death rate in babies? The intraoperative death rate quoted of 8.3/1000 for infants under one month seemed more realistic than the optimistic replies from colleagues. The intraoperative death rate of children between one to 12 months of 0.8/1000 seemed higher than I imagined, but will influence what I say to parents when seeking informed consent in the future.
Unusually for a textbook, it held my interest and attention and was readable and will influence my clinical practice in the future.
